Inhibitory effect of cerebrospinal fluid on the growth of meningococci and pneumococci

M HASSAN-KING, HC WHITTLE, BM GREENWOOD

From the Department of Medicine, Ahmadu Bello University Hospital, Zaria, Nigeria

SUMMARY Initial cerebrospinal fluid (CSF) samples obtained from patients with pneumococcal meningitis usually contain far greater numbers of bacteria than initial CSF samples obtained from patients with meningococcal meningitis. Normal CSF was found to have an inhibitory effect on the growth of group A meningococci but not on type 1 pneumococci. The inhibitory effect of normal CSF was abolished by dialysis, indicating that the inhibitory factor has a low molecular weight. Heating normal CSF to 62.5°C for 30 min resulted in a considerable reduction in the inhibitory effect, indicating that the inhibitory factor is heat labile.

Initial cerebrospinal fluid (CSF) samples obtained from patients with pneumococcal meningitis usually contain far greater numbers of bacteria than initial CSF samples obtained from patients with meningococcal meningitis The high bacterial counts found in patients with pneumococcal meningitis may relate to the poor prognosis of patients with this condition. In purulent meningitis bacteria multiply mainly in the meninges, but the CSF acts as the circulating medium through which bacteria are carried to infect other parts of the subarachnoid space. It is possible that the high number of bacteria found in pneumococcal CSFs may be due to the fact that normal CSF serves as an enhancing medium for the growth of pneumococci while it has the opposite effect on the growth of meningococci. The object of this investigation was to test the validity of this supposition.

Material and methods

CSF SAMPLES

Normal CSF samples were obtained from patients suspected on clinical grounds of having meningitis but whose CSF subsequently proved to be normal, as shown by the absence of bacteria and white blood cells. Samples were collected before the start of any treatment.

CSF samples were obtained from patients with meningococcal or pneumococcal meningitis on the day of admission to hospital, before the start of antibiotic treatment. Diagnosis was confirmed by countercurrent immunoelectrophoresis1 or latex agglutination.2

Routine Laboratory Investigations

White cell and bacterial counts were performed on CSF samples as soon as possible after collection. White cells were counted in an improved Neubauer counting chamber. CSF was diluted 1/10 in counting fluid. Bacteria were counted in a Thoma counting chamber using a phase contrast microscope. Turbid samples were diluted appropriately in phosphate buffered saline (PBS) so that there were between two and 10 bacteria per square. Pairs of bacteria were counted as one; bacteria present within a leucocyte were not counted. After white cell and bacterial counts had been made samples were centrifuged for 10 min at 3000 rpm and the supernatant removed and stored at −20°C. Deposits were cultured on blood agar plates for pneumococci and on Mueller Hinton agar plates containing polymyxin and vancomycin for meningococci. Organisms were identified by standard bacteriological methods, using the optochin test for pneumococci and group specific antisera for typing meningococci.

Measurement of Bacterial Growth in Normal and Diseased CSF Samples

3H-thymidine assay

Ten strains of group A meningococci and 10 strains of type 1 pneumococci isolated from patients with...
Inhibitory effect of cerebrospinal fluid on the growth of meningococci and pneumococci

Meningococci were used. A loopful of an 18 h culture of each organism was inoculated into 10 ml triptase soya broth (TSB) and incubated for up to 3 h at 37°C in a shaking water bath to achieve log phase culture. The bacteria were then washed twice in medium 199 and suspended in the same medium at a concentration corresponding to an optical density of 0.3, measured at 650 nm in a Pye Unicam SP 600 ultraviolet spectrophotometer. Each strain of bacteria was grown in two diseased CSF samples, including the one from which it was isolated, normal CSF, and medium 199 adjusted to a pH of 7.3. Reaction mixtures were set up in duplicate in sterile Falcon plastic tubes, comprising 0.1 ml bacterial suspension and 0.4 ml CSF or medium 199. One microcurie of 6H-thymidine solution, specific activity 5 Ci/mmol (185 G Bq) (Radiochemical Centre, Amersham), was added to each tube with a Hamilton precision syringe. The tubes were incubated at 37°C in a shaking water bath for 2 h, after which time the labelling procedure was terminated by washing the bacteria twice in cold PBS at 4°C. The bacteria were solubilised with 10% trichloroacetic acid and 1N sodium hydroxide. Digests (0.1 ml) were transferred to glass scintillation vials containing 10 ml of scintillation fluid. The scintillation fluid was made up of toluene based NE 233 containing 20% solubiliser NE 520 to incorporate water in the sample. Any possibility of chemiluminescence or quenching was eliminated by neutralising the samples with 10 μl of 1N glacial acetic acid. The samples were left for 30 min at room temperature before counting for 1 min in a Nuclear Enterprise LSC 1 liquid scintillation counter.

**Colony counting method**

A loopful of an 18 h culture of each isolate was incubated in TSB as previously described. The concentration of each organism was adjusted in sterile PBS to contain 10⁸ organisms/litre. Bacterial suspension (0.1 ml) was added to 0.4 ml of normal CSF or medium 199 in sterile Falcon plastic tubes. Samples (50 μl) were then removed from each tube and plated on to previously dried Mueller-Hinton agar plates for meningococci or on to similarly treated blood agar plates for pneumococci. The tubes were incubated at 37°C in a shaking water bath. At hourly intervals 50 μl samples were removed from each tube and plated out as above. The experiment was allowed to run for 5 h, after which time the plates were incubated overnight at 37°C in 5% carbon dioxide and bacterial colonies counted with a Galenkamp colony counter.

**Characterisation of the inhibitory factor**

*Removal of immunoglobulins from normal CSF*

Aliquots of normal CSF were mixed with equal volumes of a 1/10 dilution of anti-whole-human-immunoglobulin antiserum (Hyland Laboratories). The mixture was incubated at 37°C for 1 h and then for 24 h at 4°C. It was then centrifuged for 20 min at

![Fig. 1](http://jcp.bmj.com/)

*Fig. 1* Growth of meningococci and pneumococci, as measured by thymidine uptake in medium 199 (M 199), in normal cerebrospinal fluid (NCSF) and in CSF from patients with meningococcal (MCSF) or pneumococcal (PCSF) meningitis. Horizontal bars indicate mean counts/min (CPM).
12,000 rpm, after which the supernatant was removed and used for growing meningococci. All the procedures were carried out under sterile conditions.

**Effect of heating normal CSF**

Pooled normal CSF was tested for inhibitory activity on meningococci after heating at 56°C and 62.5°C for 30 min.

**Effect of dialysing normal CSF**

Pooled normal CSF was dialysed overnight against PBS and then tested for inhibitory activity on meningococci. Dialysis was carried out in Visking tubing with a pore size of about 10,000 daltons.

**Results**

**CSF bacterial counts in meningococcal and pneumococcal meningitis**

The bacterial counts found in initial CSF samples from 27 sequentially studied patients with pneumococcal meningitis (mean 235.8 × 10^9/l; range 2.2–1000 × 10^9/l) were considerably higher than those found in CSF samples obtained from 24 consecutive patients with group A meningococcal meningitis (mean 30.6 × 10^9/l; range 1.2–124 × 10^9/l) (p < 0.001). In contrast, the mean white cell count in the CSF of 27 sequentially studied patients with pneumococcal meningitis (mean 7.0 × 10^9/l; range 0.77–10^9/l) was similar to the mean white cell count recorded in 24 consecutive patients with group A meningococcal meningitis (mean 11.4 × 10^9/l; range 0.3–50 × 10^9/l).

**Growth of meningococci and pneumococci in normal and diseased CSF**

The growth of meningococci and pneumococci, as assessed by thymidine uptake, in medium 199, in normal CSF, and in CSF obtained from patients with meningococcal or pneumococcal meningitis is shown in Fig. 1. The growth of meningococci in normal CSF was significantly less than that in medium 199 (p < 0.001). In contrast, pneumococci grew equally well in normal CSF and in medium 199. Growth of meningococci was significantly inhibited by CSF from patients with pneumococcal meningitis (p < 0.001), and the growth of pneumococci was significantly inhibited by CSF from patients with meningococcal meningitis (p < 0.01). Pneumococci showed a higher growth rate in homologous CSF than did meningococci.

The growth rates of meningococci and pneumococci in medium 199 and in normal CSF as assessed by colony counting are shown in Figs. 2 and 3. Growth of meningococci, but not pneumococci, was inhibited significantly by normal CSF.

**Nature of the inhibitory factor in normal CSF**

The nature of the inhibitory factor present in normal

---

**Fig. 2** Growth of meningococci in medium 199 (M 199) and in normal cerebrospinal fluid (CSF). Points represent mean ± 1 standard error of the mean; n = number of experiments.

**Fig. 3** Growth of pneumococci in medium 199 (M 199) and in normal cerebrospinal fluid. Points represent mean ± 1 standard error of the mean; n = number of experiments.
Inhibitory effect of cerebrospinal fluid on the growth of meningococci and pneumococci

Table 1  Cerebrospinal fluid effect of dialysis on the inhibitory activity of normal (CSF) on the growth of meningococci.

<table>
<thead>
<tr>
<th>Culture medium</th>
<th>Counts/min (mean and range)</th>
<th>% inhibition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medium 199</td>
<td>23 361 (20 653–28 447)</td>
<td></td>
</tr>
<tr>
<td>Normal CSF</td>
<td>14 454 (11 003–17 906)</td>
<td>38 (23–53)</td>
</tr>
<tr>
<td>Normal CSF after dialysis</td>
<td>29 796 (24 240–32 769)</td>
<td>0</td>
</tr>
</tbody>
</table>

Results of three experiments are shown.

Table 2  Effect of heat on the inhibitory activity of normal cerebrospinal fluid (CSF) on the growth of meningococci

<table>
<thead>
<tr>
<th>Culture medium</th>
<th>Counts/min (mean and range)</th>
<th>% inhibition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medium 199</td>
<td>21 012 (20 653–21 400)</td>
<td></td>
</tr>
<tr>
<td>Normal CSF</td>
<td>12 578 (11 003–14 191)</td>
<td>40 (32–48)</td>
</tr>
<tr>
<td>Normal CSF</td>
<td>9914</td>
<td>53</td>
</tr>
<tr>
<td>56°C for 30 min</td>
<td>(7902–11 926)</td>
<td>(43–62)</td>
</tr>
<tr>
<td>Normal CSF</td>
<td>18 655 (18 310–19 001)</td>
<td>11</td>
</tr>
<tr>
<td>62.5°C for 30 min</td>
<td>(11 821–14 810)</td>
<td>(10–13)</td>
</tr>
</tbody>
</table>

Results of three experiments are shown.

Table 3  Effect of the removal of immunoglobulins on the inhibitory activity of normal cerebrospinal fluid (CSF) on the growth of meningococci

<table>
<thead>
<tr>
<th>Culture medium</th>
<th>Counts/min (mean and range)</th>
<th>% inhibition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medium 199</td>
<td>21 442 (20 173–22 811)</td>
<td></td>
</tr>
<tr>
<td>Normal CSF</td>
<td>13 209 (11 821–14 810)</td>
<td>38 (31–45)</td>
</tr>
<tr>
<td>Normal CSF</td>
<td>12 805 (11 400–14 401)</td>
<td>40 (33–47)</td>
</tr>
</tbody>
</table>

Results of three experiments are shown.

CSF was investigated by studying the effect of heating, dialysis, and removal of immunoglobulins. The inhibitory activity of normal CSF on meningococci was removed by dialysis (Table 1), reduced by heating to 62.5°C (Table 2), but it was not impaired by incubation of CSF with antiimmunoglobulin serum (Table 3).

Discussion

Examination of CSF from patients with pyogenic meningitis immediately after collection showed that samples from patients with pneumococcal meningitis tended to have higher CSF bacterial counts than samples from patients with meningococcal meningitis. The mean CSF bacterial count of patients with pneumococcal meningitis was eight times higher than that observed in patients with meningococcal meningitis, a difference similar to that found in a previous study undertaken in our laboratory, in which a 10 fold difference was found.³ Bacteria present within CSF leucocytes were not counted, but in our experience few CSF leucocytes contain bacteria before the start of treatment in patients with either meningococcal or pneumococcal meningitis. CSF white cell counts were considerably lower than CSF bacterial counts and similar in both groups of patients. Even if it is assumed that each CSF leucocyte from a patient with meningococcal meningitis contained one pair of bacteria while none in the CSF of patients with pneumococcal meningitis did so, a five fold difference in total CSF bacterial count between the two groups of patients would still have been observed.

The results of our study, which have shown that normal CSF has an inhibitory effect on the growth of meningococci but not on pneumococci, provide one possible explanation for the higher CSF bacterial count of patients with pneumococcal meningitis compared with patients with meningococcal meningitis. The inhibitory effect was abolished by dialysis of normal CSF, indicating that the inhibitory factor has a low molecular weight. Heating normal CSF to 62.5°C for 30 min resulted in a considerable reduction in the inhibitory effect, indicating that the inhibitor is heat labile at this temperature. Heating normal CSF to 56°C for 30 min, however, enhanced inhibition of meningococcal growth. Antibody does not seem to be the inhibitory factor since removal of immunoglobulins from normal CSF did not result in the abolition of the inhibitory effect. The results of these studies also showed that meningococci were inhibited in pneumococcal CSF and vice versa. This could possibly be attributed to increased lysozyme content in the two types of diseased CSF.⁴

Although there have not been any previous reports of normal CSF exerting an inhibitory effect on bacterial growth, there are a number of precedents for biological fluids showing such an effect on bacteria. Inhibition of bacterial growth may result from a series of complex reactions involving substances normally present in body fluids or secretions and bacterial products. For example, ascorbic acid in conjunction with hydrogen peroxide has a bactericidal effect on a number of Gram negative organisms.⁵ Ascorbic acid is present in normal CSF.⁶ It is of low molecular weight (176.12) and therefore dialysable. Hydrogen peroxide is produced during normal metabolic activity of bacteria. It is therefore conceivable that such an inhibitory mechanism on the growth of meningococci might be operating in normal CSF.

Another inhibitory system affecting bacterial growth is that mediated through certain organic
acids present in normal CSF such as lactic acid and pyruvic acid. If lactic acid was the important factor, however, samples from patients with meningitis would be expected to be much more inhibitory than normal CSF. This was not the case.

Regardless of its exact mechanism, the inhibitory effect of CSF on the growth of meningococci, but not pneumococci, may be one of the reasons why patients with pneumococcal meningitis have higher CSF bacterial counts than patients with meningococcal meningitis and why the prognosis of patients with pneumococcal meningitis is so much worse than that of patients with meningococcal meningitis.

BMG and HCW were supported by the United Kingdom Medical Research Council.

References


Requests for reprints to: Dr M Hassan-King, Medical Research Council Laboratories, Fajara, Near Banjul, The Gambia, West Africa.
Inhibitory effect of cerebrospinal fluid on the growth of meningococci and pneumococci.

M Hassan-King, H C Whittle and B M Greenwood

doi: 10.1136/jcp.37.4.428

Updated information and services can be found at:
http://jcp.bmj.com/content/37/4/428

**Email alerting service**

These include:

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/